LKFT

Lakefront Biotherapeutics NV

A Belgian biopharmaceutical company that develops medicines for immunology and oncology, including T-cell engagers for cancer. It was founded in 1999 as a joint venture between Crucell and Tibotec, and for decades operated as Galapagos NV before renaming itself Lakefront Biotherapeutics in 2026. The name honors the Chicago lakefront where its CEO runs each morning and the lakes around its Mechelen home.

American Depositary Shares, each representing one ordinary share